256 completed, 65 recruiting, 28 active not recruiting, 21 unknown. 282 Not applicable, 42 Phase 2, 31 Phase 4, 15 Phase 1, 9 Phase 3.
Follow Centre for Addiction and Mental Health: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Remote Digital Assessments for Cognitive Disorders Mild Cognitive Impairment (MCI), Alzheimer Disease (AD) | Not yet recruiting | Centre for Addiction and Mental Health | 60 | 2026-11-01 | 2026-10-20 | |
| Prescribing the Right Agent for Depression in Adults PRADA Tool, PETRUSHKA Tool - Major Depressive Disorder (MDD) | Not applicable | Not yet recruiting | University of Oxford | 2142 | 2026-10-01 | 2026-10-09 |
| Group Dialectical Behaviour Therapy (DBT) Skills Training for First Episode Psychosis group DBT - Psychosis | Not applicable | Not yet recruiting | Centre for Addiction and Mental Health | 32 | 2026-09-15 | 2026-09-16 |
| Optimizing Treatment for Depressed Parents of Children With Emotional and Behavioural Problems ADAPT Treatment, Incredible Years Parenting Program (IYPP) - Depression / Major Depressive Disorder, Conduct Disorders in Children | Not applicable | Recruiting | University of Toronto | 180 | 2026-08-01 | 2026-08-06 |
| Identifying Biomarkers of Response to Digital Interventions for Mood Disorders Online Cognitive Behavioural Therapy - Depression / Major Depressive Disorder, Bipolar Disorder (BD) | Not applicable | Enrolling by invitation | Centre for Addiction and Mental Health | 200 | 2026-07-28 | 2026-08-27 |
| Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression Psilocybin - Treatment-Resistant Depression | Phase 2 | Recruiting | Centre for Addiction and Mental Health | 40 | 2026-07-03 | 2026-08-21 |
| Smoking Harm Reduction Using E-cigarettes and Cytisine E-cigarette e-liquid, Cytisine - Tobacco Smoking, Harm Reduction | Not applicable | Not yet recruiting | Centre for Addiction and Mental Health | 6000 | 2026-05-01 | 2026-03-19 |
| Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis d-DBT - Clinical High Risk for Psychosis (CHR) | Not applicable | Recruiting | Centre for Addiction and Mental Health | 60 | 2026-04-28 | 2026-09-09 |
| Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder Psilocybin 25 mg, Placebo - Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD) | Phase 2 | Not yet recruiting | Centre for Addiction and Mental Health | 30 | 2026-03-01 | 2026-02-12 |
| Efficacy of an EMDR App for PTSD and SUD A-EMDR, Treatment as Usual (TAU) - Posttraumatic Stress Disorder (PTSD), Substance Use Disorders | Not applicable | Recruiting | Centre for Addiction and Mental Health | 24 | 2026-01-20 | 2026-05-22 |
| The Use of tDCS for Vaping Reduction Active tDCS, Sham tDCS - Vaping, Addiction | Not applicable | Recruiting | Centre for Addiction and Mental Health | 40 | 2026-01-01 | 2026-03-19 |
| Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect? Haloperidol, Placebo, Insulin Lispro - Brain Insulin Sensitivity, Healthy Controls | Phase 4 | Recruiting | Centre for Addiction and Mental Health | 35 | 2025-12-11 | 2026-04-02 |
| Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Treatment Seeking Smokers Brief alcohol intervention - Alcohol Misuse | Not applicable | Completed | Centre for Addiction and Mental Health | 77 | 2025-11-20 | 2026-06-11 |
| THC Titration of High-Potency Cannabis Concentrates Cannabis (30% THC Concentrate), Cannabis (60% THC Concentrate), Cannabis (90% THC Concentrate) - THC | Not applicable | Recruiting | Centre for Addiction and Mental Health | 48 | 2025-10-01 | 2026-06-11 |
| Testing Interventions for Borderline Personality Disorder. Sage, Supportive Individual Psychotherapy - Borderline Personality Disorder | Phase 2 | Recruiting | York University | 304 | 2025-09-01 | 2026-04-01 |
| Characterizing Synaptic Density in Treatment Resistant Depression PET scans - Treatment Resistant Depression, Depression - Major Depressive Disorder | Recruiting | Unity Health Toronto | 45 | 2025-08-22 | 2026-09-15 | |
| Theta-Burst Stimulation to Treat Depression Spaced iTBS, Compressed iTBS - Major Depressive Disorder (MDD) | Phase 1 | Recruiting | Centre for Addiction and Mental Health | 84 | 2025-06-01 | 2025-06-24 |
| Temporal Interference and Depression Temporal Interference stimulation, Sham stimulation - Major Depressive Disorder | Not applicable | Recruiting | Unity Health Toronto | 30 | 2025-05-15 | 2025-04-24 |
| Magnetic Seizure Therapy for Schizophrenia - Trial Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT) - Treatment Resistant Schizophrenia, Schizophrenia | Not applicable | Recruiting | Centre for Addiction and Mental Health | 80 | 2025-04-22 | 2026-02-03 |
| Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) Psilocybin 25 mg, Risperidone 1 MG - Treatment Resistant Depression | Phase 2 | Recruiting | Centre for Addiction and Mental Health | 12 | 2025-04-21 | 2026-10-19 |
Showing 20 of 409. Sign in to see all of them.
Depression (71) · Depressive Disorder, Major (66) · Schizophrenia (62) · Psychotic Disorders (42) · Tobacco Use Disorder (29) · Smoking Cessation (26) · Substance-Related Disorders (25) · Alcoholism (23) · Mental Disorders (23) · Bipolar Disorder (21) · Depressive Disorder, Treatment-Resistant (21) · Anxiety Disorders (18) · Cognitive Dysfunction (17) · Smoking (16) · Alzheimer Disease (12)
Transcranial Magnetic Stimulation (21) · Cognitive Behavioral Therapy (17) · Therapeutics (17) · Ethanol (15) · Varenicline (12) · Tobacco Use Cessation Devices (10) · nabiximols (10) · Nicotine (9) · Psilocybin (9) · Transcranial Direct Current Stimulation (8) · Risperidone (7) · Magnetic Resonance Spectroscopy (6) · Nicotine Replacement Therapy (6) · Antidepressive Agents (5) · Dexetimide (5)
Canada (394) · United States (9) · India (4) · Pakistan (4) · Ethiopia (1) · Finland (1) · United Kingdom (1)
Bernard Le Foll, MD, PhD (13) · John A Cunningham, PhD (7) · John Cunningham, PhD (6) · Philip Gerretsen, MD, PhD (6) · Arun Ravindran, MD, PhD (5) · Daniel Blumberger, MD (5) · Daniel Blumberger, MD, MSc (5) · John A Cunningham, Ph.D. (5) · Laurie Zawertailo, PhD (5) · Tarek Rajji, MD (5) · Benjamin I Goldstein, MD, PhD (4) · Jeffrey H Meyer, MD, PhD (4) · Peter Selby, MD, MHSc (4) · Angela Golas, MD (3) · Ariel Graff, MD, PhD (3)
PMID 33884617, PMID 34131914, PMID 28720080, PMID 29486960, PMID 29701939, PMID 30854751, PMID 31200648, PMID 32040383, PMID 32368793, PMID 36483268, PMID 37925557, PMID 40014392, PMID 40154967, PMID 42501968, PMID 42526755, PMID 10689661, PMID 12053639, PMID 15177086, PMID 18727823, PMID 19755574, PMID 19758522, PMID 19922906, PMID 20150170, PMID 20439832, PMID 20868639, PMID 20946914, PMID 21736507, PMID 21955930, PMID 22037137, PMID 22122217, PMID 22348112, PMID 22410480, PMID 22464727, PMID 22581157, PMID 22912618, PMID 22954459, PMID 23022436, PMID 23039931, PMID 23110157, PMID 23185985, PMID 23417515, PMID 23834999, PMID 23963055, PMID 25234606, PMID 25427521, PMID 25450537, PMID 25539597, PMID 25604206, PMID 25629589, PMID 26116778
R01MH114966 (2), R01MH114970 (2), R01MH114980 (2), R01MH114981 (2), R01MH121632 (2), R01MH066992 (1), R01MH112815 (1), R01MH114969 (1), R01MH121520 (1), R21DA031906 (1), R21DA061350 (1), U01NS119562 (1)